"Patience is a Super Power" - "The Money is in the waiting"
Showing posts with label Softbank. Show all posts
Showing posts with label Softbank. Show all posts

Wednesday, July 23, 2025

Why do Nvidia and so many institutional investors own most of the shares of RXRX - Recursion Pharma

 


Why Nvidia Invested in RXRX

1. Deep AI Integration for Drug Discovery

  • In July 2023, Nvidia invested $50 million via a PIPE deal to help Recursion accelerate training of AI models for drug discovery. This investment boosted RXRX stock by about 83% immediately Reuters

  • Nvidia provided cutting-edge GPUs and access to its BioNeMo generative-AI cloud platform so Recursion could train models on its massive biological dataset MarketWatch+2.

2. Equity Stake & Strategic Synergy

  • Nvidia now holds over 7.7 million shares—approximately a 3–4% stake—making Recursion one of its top non-core holdings The Times+11

  • This aligns with Nvidia’s broader strategy of investing in AI-first companies that complement its hardware, not just selling chips.

3. Accelrating RXRX’s Supercomputer Ambitions

  • Recursion built BioHive‑2, a supercomputer powered by Nvidia’s DGX H100 GPUs. It delivers a 4x speed increase over their prior system, enabling faster model training Reuters+2T

  • This partnership helps validate Nvidia hardware in high-performance biotech applications—which can drive future sales to pharma partners.


๐Ÿฅ Broader Vision: Redefining Pharma with AI

  • Recursion uses AI, automation, and robotics to develop drugs more quickly and affordably. Its platform includes the “virtual cell” paradigm and is backed by major pharma companies like Bayer and Roche Investors+14.

  • Analysts project RXRX revenue growing at a ~65–73% CAGR through 2027—significantly above typical biotech growth—with Nvidia’s backing lending extra credibility The Motley Fool+5

✅ Summary

Nvidia's investment in RXRX is twofold:

  1. Financial Buy-In – it gains exposure to a high-growth biotech using AI and fosters long-term capital appreciation.

  2. Strategic Alignment – Nvidia deepens integration of its AI stack (hardware + BioNeMo) in the drug discovery workflow, while demonstrating its systems’ performance in real-world pharma applications.

It’s part of a broader strategy of deploying capital into AI-first companies that can both benefit from and validate Nvidia’s ecosystem, accelerating adoption across industries.


Here are the top ten institutional investors in Recursion Pharmaceuticals (RXRX), based on the most recently reported 13F filings (as of March 31, 2025) and aggregated data sources Yahoo Finance+12:


๐Ÿฆ Top 10 Institutional Holders of RXRX

Ranked by percentage ownership:

  1. ARK Investment Management LLC — 8.66% (~34.8M shares; ~$184 M) 

  2. Vanguard Group Inc. — 8.03% (~32.3M shares; ~$171 M) 

  3. Lux Ventures IV LP — 7.46% (~30.3M shares; ~$194 M) 

    1. Baillie Gifford & Co. — 6.07% (~24.4M shares; ~$129 M)
  4. BlackRock Inc. — 5.78% (~23.5M shares; ~$150 M) 

  5. SoftBank Group Corp. — 3.61% (~14.7M shares; ~$94 M) 

  6. Kinnevik AB (publ) — 3.30% (~13.4M shares; ~$86 M) 

  7. State Street Corp. — 3.22% (~13.1M shares; ~$84 M) 

  8. Mubadala Investment Co. PJSC — 3.19% (~13.0M shares; ~$83 M) 

  9. Novo Holdings A/S — 2.38% (~9.7M shares; ~$62 M) 

๐Ÿงพ Summary Table

Investor% OwnershipApprox. Shares
ARK Investment Management LLC8.66%~34.8 M
Vanguard Group Inc.8.03%~32.3 M
Lux Ventures IV LP7.46%~30.3 M
Baillie Gifford & Co.6.07%~24.4 M
BlackRock Inc.5.78%~23.5 M
SoftBank Group Corp.3.61%~14.7 M
Kinnevik AB (publ)3.30%~13.4 M
State Street Corp.3.22%~13.1 M
Mubadala Investment Co. PJSC3.19%~13.0 M
Novo Holdings A/S2.38%~9.7 M

๐Ÿ’ก Key Insights

  • Institutional investors control around 75% of RXRX's outstanding shares Nasdaq+

  • ARK and Vanguard are the two largest, with each holding over 8% of the company.

  • Lux Ventures IV LP—a prominent insider-linked investor—is effectively the third-largest stakeholder at ~7.5%.

  • Other heavyweights include Baillie Gifford, BlackRock, SoftBank, and sovereign/strategic holders like Mubadala and Novo Holdings.


Here’s a breakdown of the recent moves by institutional investors in RXRX:


๐Ÿ“ˆ Increased Positions (Recent Quarter)

  • UBS Asset Management Americas (UBS AM) added 4.15M shares (+183.7%) in Q1 2025 (~$22M) MarketBeat+

  • UBS Group AG boosted its stake by 2.57M shares (+85.4%) (~$13.6M) 

  • According to CapEdge filings (as of July 22, 2025):

    • KLP Kapitalforvaltning AS increased by +20% (~61K shares)

    • Steel Peak Wealth Management up +21% (~85K shares)

    • Prime Capital Investment Advisors boosted by +61% (~30K shares)

    • IMC‑Chicago surged +76% (~284K shares) 

๐Ÿ“‰ Reduced or Exited Positions

  • RA Capital Management, L.P. fully exited its position, selling 7.73M shares (~$41M) in Q1 2025 

  • CapEdge data shows QRG Capital Management reduced its holding by 32% (~19K shares) as of July 21, 2025 

๐Ÿ” Additional Context

  • Total institutional inflows over the past 24 months reached significantly more than outflows:

    • 83.2M shares purchased (~$550M)

    • 18.3M shares sold (~$117M) MarketBeat

    • This reflects overall upward interest, but pockets of profit-taking and rotation remain.

  • Other Q1 fourth-quarter buyers included firms like Brighton Jones, Victory Capital, and Private Advisor Group, while sellers included RA Capital prominently MarketBeatMarketBeat.


✅ Summary

  • UBS (both global and Americas units) made the largest scale-ups recently.

  • RA Capital initiated the most substantial reduction, liquidating its entire stake.

  • Mid-cap managers like KLP, Steel Peak, Prime Capital, and IMC‑Chicago also significantly expanded their RXRX positions.

  • Some smaller managers, including QRG Capital, reduced or trimmed their positions.


  • ED Note:  We are long RXRX

Monday, January 20, 2025

Androids, Humanoid Robots, whatever the label, they are coming. Now, Who is leading the charge into this lucrative, futuristic market?

 


Humanoid Robots / Androids: A 2025+ Business & Investment Report

1. Executive Summary

The humanoid-robot (or “android”) sector has moved from futuristic demonstration projects into serious R&D and early-stage commercialization. Continuous improvements in artificial intelligence, battery technology, and materials science have created a convergent point where mass production is on the horizon. This report outlines the key players, potential use cases, market drivers, and financial snapshots of the publicly traded companies most involved in developing humanoid robots.


2. Leading Companies (Ranked by Commercial Readiness & Technological Progress)

  1. Tesla (NASDAQ: TSLA)

    • Flagship Robot: Tesla Bot (“Optimus”)

    • Why #1? Strong manufacturing track record, advanced battery expertise, and vocal commitment from Tesla’s leadership to deploy humanoid robots in industrial environments. The company’s large AI/Autopilot team provides synergy for real-time control and perception.
  2. Boston Dynamics (Majority-Owned by Hyundai Motor Group, KRX: 005380)

    • Flagship Robot: Atlas

    • Why #2? Boston Dynamics leads in agility and mobility for humanoid robots. However, historically, they have been slow to commercialize. Hyundai’s ownership could accelerate production capabilities—yet their path to mass production remains more cautious.
  3. Xiaomi (HKEX: 1810)

    • Flagship Robot: CyberOne (prototype)

    • Why #3? Xiaomi’s deep roots in consumer electronics and its extensive supply chain might allow it to scale quickly if (and when) it decides to commercialize CyberOne. However, the robot remains in conceptual stages, indicating a longer timeline.
  4. SoftBank Robotics (Subsidiary of SoftBank Group, TYO: 9984)

    • Key Robots: Pepper, NAO (social robots)

    • Why #4? Although SoftBank’s Pepper and NAO are not full humanoids on par with Atlas or Optimus, SoftBank has experience in producing robots at scale. With the right pivot, the group could expand into more advanced humanoid platforms.
  5. Others (Privately Held / Early-Stage)

    • Engineered Arts (Ameca)

    • Hanson Robotics (Sophia)

    • Apptronik (Apollo)


      These companies are developing sophisticated platforms but remain private or in earlier phases of commercialization. While they showcase impressive technology, they are not directly open to public market investment (as of early 2025).

3. Most Promising Mass Production Prospects

  1. Tesla

    • Production Advantage: Proven global factory network (in the U.S., China, Germany, etc.), advanced supply chain management, and battery manufacturing expertise.
    • Stated Goal: Elon Musk has signaled a plan to deploy Tesla Bot first in Tesla factories for routine tasks, potentially scaling to consumer uses.
  2. Hyundai Motor Group (Boston Dynamics)

    • Production Advantage: A major automotive manufacturer with strong industrial capabilities.
    • Potential: Could pivot from R&D to mass production if a clear commercial application is identified (e.g., manufacturing, logistics, healthcare).
  3. Xiaomi

    • Production Advantage: Known for producing high volumes of cost-competitive consumer electronics.
    • Potential: If Xiaomi invests heavily into robotics, it could leverage existing electronics and hardware supply chains, but the path to a robust humanoid is still nascent.

4. Use Cases for Humanoid Robots

  1. Industrial & Manufacturing

    • Repetitive / Hazardous Tasks: Welding, assembly, material handling in factories.
    • 24/7 Operation: Potential to run around the clock with proper maintenance, reducing costs.
  2. Logistics & Warehousing

    • Picking and Packing: Tasks that require human-like mobility and dexterity.
    • Automated Inventory Checks: Vision-guided robots can navigate aisles and catalog products.
  3. Service & Hospitality

    • Customer Interaction: Reception, information desks, basic concierge tasks.
    • Entertainment: Theme parks, advertising, or brand engagement.
  4. Healthcare & Elder Care (Longer-Term)

    • Patient Assistance: Helping move patients, assist nurses, or provide companionship.
    • Household Tasks: Potentially assisting the elderly or disabled with daily living activities.
  5. Research & Education

    • Human-Robot Interaction: Universities and labs exploring advanced AI, robotics, and ethics.
    • Demonstration Platforms: Showcases for next-gen robotics in STEM education.

5. Why This Market Is Worth Pursuing

  1. Rising Labor Costs & Shortages

    • Many developed nations face workforce shortages in manufacturing, logistics, and elder care. Humanoid robots can fill labor gaps for routine or physically demanding tasks.
  2. Rapid Advancements in AI

    • Large language models, computer vision, and sensor fusion systems enable robots to perceive and act more autonomously, increasing their utility and reducing the need for custom programming.
  3. Cost Reduction from Scale

    • As robotics manufacturing matures, component costs (motors, sensors, processors) continue to drop, making the entry price more attractive for businesses seeking automation.
  4. Potential for Wide Adoption

    • The concept of a general-purpose robot—capable of multiple tasks—expands far beyond the traditional limitations of fixed industrial robotics.
  5. Investor Appeal

    • Robotics is a high-growth, high-visibility sector that often commands premium valuations. Early involvement in leading companies can yield significant returns if mass adoption materializes.

6. Financial Snapshots (Publicly Traded Leaders)

Below are approximate figures and highlights as of Q1 2025. (Historical data from public sources; forward-looking figures are estimates.)

Tesla (NASDAQ: TSLA)

  • Market Cap: Often in the range of USD 700–900 billion (fluctuates with market conditions).
  • Revenue (Trailing 12 Months): Over USD 120+ billion, primarily from EV sales, energy storage, and services.
  • R&D Expenditure: Estimated at ~5-7% of revenue, a portion now directed toward Optimus/Bot development.
  • Key Investment Note: Tesla’s robotics initiative is still a small part of total operations, but strategic leadership sees it as a future growth area.

Hyundai Motor Group (KRX: 005380)

  • Market Cap: Typically in the range of USD 35–50 billion (converted from KRW), depending on the unit of Hyundai in question (Hyundai Motor Company, Hyundai Mobis, etc.).
  • Revenue (Trailing 12 Months): Over USD 100+ billion across all automotive businesses.
  • R&D Expenditure: Hyundai invests billions annually in advanced tech; the portion allocated to Boston Dynamics is not separately detailed but is significant.
  • Key Investment Note: Boston Dynamics is not yet a large revenue driver but is a high-tech asset for Hyundai’s future robotics ambitions.

Xiaomi (HKEX: 1810)

  • Market Cap: Historically in the range of USD 40–60 billion.
  • Revenue (Trailing 12 Months): Often exceeding USD 50+ billion, primarily from smartphones, IoT devices, and internet services.
  • R&D Expenditure: A significant chunk is directed at electronics and software development; robotics is still a small but potentially growing slice.
  • Key Investment Note: Xiaomi’s robotics ambitions are nascent. If CyberOne or future android initiatives mature, Xiaomi could leverage its massive electronics ecosystem for rapid scaling.

SoftBank Group (TYO: 9984)

  • Market Cap: Historically in the range of USD 50–70+ billion (exchange-rate dependent).
  • Revenue (Trailing 12 Months): Over USD 40+ billion across telecom, investment, and tech holdings.
  • R&D & Investment: SoftBank is known more for large-scale tech investments (e.g., Vision Fund) rather than direct R&D. SoftBank Robotics (Pepper, NAO) could expand or pivot with enough internal capital.
  • Key Investment Note: SoftBank’s robotics revenues are relatively modest vs. broader group revenues, but there is potential if they decide to scale advanced humanoid platforms.

7. Strategic Outlook & Considerations

  1. Timeline Uncertainties: The gap between a compelling prototype and full-scale mass production can be substantial. Investors should be mindful of potential delays in product readiness, regulatory issues, and demand uncertainties.

  2. Competitive Dynamics: Specialized robotics companies (private or public) may emerge or partner with established manufacturers, posing either competition or M&A opportunities for the market leaders.

  3. Regulatory & Societal Impact: Worker displacement, ethical concerns, and robotics safety standards will shape how fast humanoid robots can be deployed in certain regions or industries.

  4. Partnership Opportunities: Automakers, tech giants, and AI firms may form alliances to spread R&D costs and accelerate time to market.

  5. Market Size: Conservative estimates see the humanoid robot market (and related services) potentially reaching tens of billions of USD in annual revenue by the 2030s, primarily driven by industrial and service robots.


8. Conclusion

Humanoid robots are at a pivotal stage. As of 2025, Tesla leads in potential mass production, Boston Dynamics/Hyundai are top in advanced locomotion and robotics R&D, Xiaomi shows promise with consumer-electronics scale, and SoftBank remains influential as a tech investor and producer of social robots. The sector’s future hinges on bringing production costs down, improving AI-driven autonomy, and successfully identifying (and serving) large-scale commercial applications.

For investors, the opportunity is significant but carries inherent technology, execution, and adoption risks. The potential payoff lies in capturing a slice of a transformative market—one that could redefine labor, service, and industrial operations for decades to come.


Final Note: Monitoring corporate disclosures, investor calls, and prototype demonstrations will be critical to staying informed. As with any emerging technology, the early winners may be those with deep pockets, top-tier engineering, and a clear path to practical use cases.

Related Articles:

Robots and Automation - From factory bots to Robo Taxis and Humanoids. Who are the leading companies?